- MGC Pharmaceuticals (MXC) receives a US$1 million (A$1.43 million) order for its anti-inflammatory product, ArtemiC
- The order comes after the company updated its US Supply and Distribution agreement with AMC to include its ArtemicC product
- Production of ArtemiC Rescue will commence immediately and will be delivered to AMC over the next three months
- Additionally, the companies are working to potentially bring MGC Pharma’s phyto-cannaboid medicines, CogniCann and CannEpil to the US market
- Shares are trading flat at 1.9 cents today at 1:04 pm AEST
MGC Pharmaceuticals (MXC) has received a US$1 million (A$1.43 million) order for its anti-inflammatory product, ArtemiC.
The order came after the company updated its US Supply and Distribution agreement with AMC to include its ArtemicC product.
Production of ArtemiC Rescue will commence immediately and will be delivered to AMC over the next three months.
Additionally, the companies are working to potentially bring MGC Pharma’s phyto-cannaboid medicines, CogniCann and CannEpil to the US market under existing early patient access schemes.
Managing Director and CEO Roby Zomer said he is looking forward to AMC’s insight for the future clinical development of ArtemiC.
“The inclusion of ArtemiC in the AMC Supply and Distribution agreement recognises the progress that MGC Pharma has made in the development of this product, and the receipt of AMC’s initial US$1 million order is a great step for the company as it further expands its reach into the global market for a product which has demonstrated great potential from clinical trial data to date,” he said.
Shares were trading flat at 1.9 cents today at 1:04 pm AEST.